REDEYE GROWTH DAY

JUNE 1, 2023

JENS LINDBERG, CEO MEDIVIR AB

MEDIVIR

Important notice

You must read the following before continuing. The following applies to this document and the information provided in this presentation by Medivir AB (publ) (the "Company") or any person on behalf of the Company and any other material distributed or statements made in connection with such presentation (the "Information"), and you are therefore advised to carefully read the statements below before reading, accessing or making any other use of the Information. In accessing the Information, you agree to be bound by the following terms and conditions.

The Information does not constitute or form part of, and should not be construed as, an offer of invitation to subscribe for, underwrite or otherwise acquire, any securities of the Company or a successor entity or any existing or future subsidiary or affiliate of the Company, nor should it or any part of it form the basis of, or be relied on in connection with, any contract to purchase or subscribe for any securities of the Company or any of such subsidiaries or affiliates nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. Specifically, this presentation does not constitute a "prospectus" within the meaning of the U.S. Securities Act of 1933, as amended.


The Information may not be reproduced, redistributed, published or passed on to any other person, directly or in directly, in whole or in part, for any purpose. The Information is not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident of, or located in, any locality, state, country or other jurisdiction where such distribution or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction. The Information is not for publication, release or distribution in the United States, Australia, Canada or Japan, or any other jurisdiction in which the distribution or release would be unlawful.

All of the Information herein has been prepared by the Company solely for use in this presentation. The Information contained in this presentation has not been independently verified. No representation, warranty or undertaking, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the Information or the opinions contained herein. The Information contained in this presentation should be considered in the context of the circumstances prevailing at that time and will not be updated to reflect material developments which may occur after the date of the presentation. The Company may alter, modify or otherwise change in any manner the content of this presentation, without obligation to notify any person of such revision or changes.

This presentation may contain certain forward-looking statements and forecasts which relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on the Company's operations, financial position and earnings. The terms "anticipates", "assumes", "believes", "can", "could", "estimates", "expects", "forecasts", "intends", "may", "might", "plans", "should", "projects", "will", "would" or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statements. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in a forward-looking statement or affect the extent to which a particular projection is realized. Factors that could cause these differences include, but are not limited to, implementation of the Company's strategy and its ability to further grow, risks associated with the development and/or approval of the Company's potential market and industry, the ability to develop new products, the impact of competition, changes in general economy and industry conditions and legislative, regulatory and political factors. While the Company always intends to express its best judgment when making statements are not a guarantee of its performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances. Many of these risks are outside of the Company's control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this presentation are made only as of the date hereof. The Company does not undertake, and specifically decline, any obligation to update any such statements or to publicly announce the results of any revisions to any of such statements to reflect future events or developments.



Medivir - A Swedish biotech focused on development of innovative treatments for cancer





Focused strategy with clear priority for first-in-class, orphan drug in liver cancer

Active partnering strategy for additional value creation across product portfolio



Highlights during last quarter

Fostrox development in liver cancer picking up speed

- Recommended phase II dose established at 30 mg for fostrox combination with Lenvima, first patients dosed in fostrox + Lenvima phase 2a shortly after study initiation.
- Longest running patients still on treatment for 9 months without disease progression
- Rapid recruitment in expansion phase with 7 patients already dosed and 6 in screening
- New data, showing synergistic efficacy of fostrox in triple combination with anti-PD1 & Lenvima in experimental tumor models, presented at the AACR Conference.

Encouraging progress across outlicensed projects

- IGM-8444 + birinapant combination study has completed the fourth dose escalation cohort during Q1, no DLTs observed to date. Now enrolling in cohort number five.
- Tango Therapeutics presented new data at AACR conference showing single agent activity as well as strong synergy with PARP inhibitor in both BRCA1/2 mutant & HRD+ in nonclinical models & re-iterated intention to file an IND mid-2023.
- INFEX Therapeutics announced that the MBLI program (MET-X) received FDA QIDP designation.

Pipeline overview – in-house development & assets for partnering

PROJECT	PARTNER	DISEASE AREA	PRE- CLINICAL	PH 1	PH 2	PH 3	ON MARKET	FINANCIALS	POTENTIAL NEXT EVENT(S)
IN-HOUSE PROGRAM									
Fostroxacitabine bralpamide	In-house development	HCC (mono) HCC (combo)						100% Medivir	Selection of dose(s)Dose expansion
PARTNERING PROGRAMS									
Xerclear	GSK, SYB	Herpes	_					Royalties	 Registration in China
Remetinostat	TBD	CTCL, BCC, SCC						TBD	 Partnering agreement
MIV-711	TBD	Osteoarthirtis						TBD	 Partnering agreement
Birinapant	IGM Biosciences	Solid tumors						Milestones (up to \$350m) & royalties	Selection of doseExpansion cohort(s)
USP-1	Tango Therapeutics	Cancer						Milestones & royalties	US INDInitiating phase I
USP-7	Ubiquigent Limited	Cancer						Revenue share	 Partnering agreement for Ubiquigent
MBLI (MET-X)	INFEX Therapeutics	Infection						Revenue share	Initiating phase IPartnering agreement


Projects developed by Medivir

Projects developed by external partner

Fostroxacitabine bralpamide (fostrox)



Fostrox – Combination of proven mechanisms





Fostrox – 3 key elements to overcoming shortcomings of traditional chemotherapy





Same pro-drug approach used successfully in HCV to ensure **liver targeted exposure**




Cell killing selectivity; cytotoxic with strong link between DNA replication & DNA damage



L-nucleoside approach to **avoid resistance mechanisms**



Recommended phase II dose for fostrox + Lenvatinib at 30 mg with no DLTs, rapidly including patients in dose expansion




Patient Population:

- 2L & 3L advanced inoperable HCC, Child-Pugh A,
- Progressed on or intolerant of 1L or 2L SOC therapy for HCC

Currently ongoing at 15 sites in UK, Spain & Korea




Combination arm of fostrox + Lenvima generating strong interest from clinicians & patients, 10 patients on active treatment





2L advanced HCC studies highlighting significant unmet medical need




Low response rates & short time to progression across 2L studies indicating very high unmet medical need


Anti-PD-1's + kinase inhibitors showing similar response rates, highlighting need for different modes of action



Fostrox – selection of combination arm for phase 2b in 2L advanced HCC



With fostrox initially targeting 2L advanced patients, Lenvima combination best aligned with currrent clinical practice





Fostrox + Lenvima arm recruiting with speed is encouraging as multiple factors favors this as the "best" arm for 2L



Ability to increase fostrox dose to 30 mg in combination with lenvatinib, without DLTs




Encouraging with patients staying on treatment in this difficult-to-treat population



Combination of fostrox + Lenvima perfectly aligned with treatment guidelines moving forward




Fostrox – possible opportunities for combination arm not selected for 2L advanced HCC






Fostrox combination with anti-PD-1 could be an option in a triple combination in 1L advanced HCC




Fostrox could provide new opportunity as triple combination showing synergistic anti-tumor efficacy

Fostrox induces increased expression of PD-L1, LAG-3 & CD8, for increased immune-mediated anti-tumor activity¹

Fostrox + anti-PD-1 & Lenvima combination data at AACR conference 2023 supporting synergistic efficacy¹







Fostrox – A unique, first-in-class potential treatment for primary liver cancer



Significant unmet need & commercial potential

Unique MoA that selectively targets cancer in the liver to minimize systemic side effects

	•	

Strong potential for attractive combinations across lines of treatment



Fostrox Scientific Counsel to support shaping our future development



- Dr. Richard Finn
- Ronald Regan UCLA Medical Center, Santa Monica, CA, USA
- Professor of Medicine, Div Hematology/Oncology, Head of the Translational Research Laboratory
- PI Imbrave150, LEAP-002, Keynote-240 studies



- Dr. Jeff Evans
- Beatson West of Scotland Cancer Center, Glasgow, UK
- Professor of Translational Cancer Research. Pl in MIV-818-201 study



Dr. Arndt Vogel

- Center for Gastroenterology, Hepatology & Endocrinology, Hannover, Germany
- Prof Hepatology & Head GI-Cancer/ Personalized Medicine
- PI Imbrave150, Himalaya, Keynote-224, LEAP-002 studies
- Chairman HCC Cancer Study Group of AIO
- Member of ESMO Guidelines Steering Committee



Dr. Maria Reig

•

- Liver Cancer Unit. Hospital Clínic BCLC group, Villarroel, Barcelona, Spain
- Head of unit Oncology, member of Barcelona Clinic Liver Cancer (BCLC) prognosis and treatment strategy group
- PI in MIV-818-201 study



- Dr. Jeong Heo
- Division of Gastroenterology and Hepatology, Pusan National University, South Korea
- Professor of Internal head of clinical trial unit for Phase I-IV hepatitis & HCC
- PI Himalaya,
- PI in MIV-818-201 study



Strategic evolution & vision for fostrox in liver cancer

Fostrox; Go-To option for combinations across liver related tumors

Early lines HCC

Launch as preferred combination partner in select patient groups in early lines HCC with either TKI or PD-1

BACKBONE IN HCC

Establish as backbone for combinations across HCC with potential for triple combinations & earlier lines

Beyond HCC

Explore potential in other liver related tumors beyond HCC such as CRC driven liver metastasis



Clinical portfolio and partnerships



Pipeline overview – in-house development & assets for partnering

PROJECT	PARTNER	DISEASE AREA	PRE- CLINICAL	PH 1	PH 2	PH 3	ON MARKET	FINANCIALS	POTENTIAL NEXT EVENT(S)
IN-HOUSE PROGRAM									
Fostroxacitabine bralpamide	In-house development	HCC (mono) HCC (combo)						100% Medivir	Selection of dose(s)Dose expansion
PARTNERING PROGRAMS									
Xerclear	GSK, SYB	Herpes	_					Royalties	 Registration in China
Remetinostat	TBD	CTCL, BCC, SCC						TBD	 Partnering agreement
MIV-711	TBD	Osteoarthirtis						TBD	 Partnering agreement
Birinapant	IGM Biosciences	Solid tumors						Milestones (up to \$350m) & royalties	Selection of doseExpansion cohort(s)
USP-1	Tango Therapeutics	Cancer						Milestones & royalties	US INDInitiating phase I
USP-7	Ubiquigent Limited	Cancer						Revenue share	 Partnering agreement for Ubiquigent
MBLI (MET-X)	INFEX Therapeutics	Infection						Revenue share	Initiating phase IPartnering agreement


Projects developed by Medivir

Projects developed by external partner

Birinapant – Continues to dose escalate in combination with IGM-8444¹

Licensing agreement¹ with IGM Biosciences

- Clinical testing of birinapant (IGM-9427) in combination with IGM-8444, a Death Receptor 5 (DR5) agonist initiated during 2021 in patients with solid tumors²
- The 4th dose escalation cohort completed with no DLTs, now dosing patients in 5th cohort.
- Potential development, regulatory and sales milestone payments up to a total of approximately USD 350 million plus tiered royalties from the mid-single digits up to midteens on net sales



Preclinical models support synergistic anti-tumor activity


IGM is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies Open-label, Multicenter, phase I Study in patients with solid tumors in two stages: a dose-escalation stage and an expansion stage (NCT04553692)

TNG348 (USP1) – CD selected & IND filing planned mid-2023

Preclinical licensing agreement, novel target moving towards the clinic in 2023

- Pre-clinical program outlicensed to Tango Therapeutics Q1 2020; TNG348 nominated as CD, IND filing planned mid-2023
- Distinct mechanism of action from PARP inhibitors with synergy in both PARPi-sensitive and resistance models
- Significant patient opportunity with BRCA1/2 mutations occuring in ~15% ovarian, 10% breast, 10% prostate, 5% endometrial and 5% pancreatic cancers
- Potential development and commercial milestone payments and low single digit royalties on future products

TNG348 synergizes in vivo with PARP inhibitor and can overcome PARP inhibitor resistance¹






MET-X (MBLI) – FDA QIDP Designation received, moving towards clinic

Potential best-in-class Metallo-β-Lactamase Inhibitor

- MET-X is a potent broad-spectrum MBL inhibitor in combination with β -lactams to restore their activity, targeting one of the most serious global threats from AMR. (Anti Microbial Resistance)
- Moving towards clinic in 2023, recently received FDA QIDP ٠ designation in January
- Revenue share agreement on all commercialisation revenue. ٠
- Recent developments in financing solutions for novel antibiotics ٠ generating increased commercial opportunity; UK "Netflix" model by NICE, PASTEUR Act in US & G7 call-to-action.
- EU proposing transferable data exclusivity vouchers as part of • new pharmaceutical legislation for AMR medicines.

MET-X restores activity of Meropenem*



*Restoration of meropenem activity in critical threat Gram-negative pathogens (519 clinical isolates of MBL-positive Enterobacterales). Clinical isolate panel containing NDM (n=385), IMP (n=44) and VIM (n=90) producers

Financial highlights Q1

Financial summary Q1, 2023

Consolidated Income Statement, summary	Q	Q1	
(SEK m)	2023	2022	2022
Net turnover	0.4	0.5	4.4
Other operating income	0.4	0.4	1.8
Total income		0.9	6.2
Other external expenses	-13.1	-25.8	-69.1
Personnel costs	-6.2	-6.2	-20.7
Depreciations and write-downs	-0.7	-0.6	-2.6
Other operating expenses	-0.3	-0.3	-1.2
Operating profit/loss	-19.6	-32.0	-87.4
Net financial items	0.7	-0.7	-1.4
Profit/loss after financial items	-18.9	-32.7	-88.8
Тах	-	-	-
Net profit/loss for the period	-18.9	-32.7	-88.8

• Net turnover for Q1 was SEK 0.4 million

- Operating loss for Q1 was SEK -19.6 million
- Cash flow from operating activities for Q1 was SEK -16.1 million
- Cash balance end of Q1 was SEK 100.8 million

Highlights during last quarter

Fostrox development in liver cancer picking up speed

- Recommended phase II dose established at 30 mg for fostrox combination with Lenvima, first patients dosed in fostrox + Lenvima phase 2a shortly after study initiation.
- Longest running patients still on treatment for 9 months without disease progression
- Rapid recruitment in expansion phase with 7 patients already dosed and 6 in screening
- New data, showing synergistic efficacy of fostrox in triple combination with anti-PD1 & Lenvima in experimental tumor models, presented at the AACR Conference.

Encouraging progress across outlicensed projects

- IGM-8444 + birinapant combination study has completed the fourth dose escalation cohort during Q1, no DLTs observed to date. Now enrolling in cohort number five.
- Tango Therapeutics presented new data at AACR conference showing single agent activity as well as strong synergy with PARP inhibitor in both BRCA1/2 mutant & HRD+ in nonclinical models & re-iterated intention to file an IND mid-2023.
- INFEX Therapeutics announced that the MBLI program (MET-X) received FDA QIDP designation.

Thank You!

0

•

`